Business Context and Reporting Period
This Form 6-K filing by RedHill Biopharma Ltd. (Nasdaq: RDHL) covers the month of December 2025, specifically dated December 15, 2025. The filing incorporates a press release announcing positive in vivo results for the company's investigational drug, opaganib, in combination with venetoclax for the treatment of Chronic Lymphocytic Leukemia (CLL). RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases, infectious diseases, and oncology, with a commercial product (Talicia) and several late-stage development programs.
Key Financial Metrics
The filing text does not provide specific financial data for RedHill Biopharma Ltd., including revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The document focuses exclusively on clinical development updates and strategic partnerships. The only financial figure mentioned is external market data: venetoclax (a competitor's product) achieved sales of approximately $2.5 billion in 2024.
Material Changes and Clinical Updates
- Opaganib and Venetoclax Combination: New in vivo study results indicate that adding opaganib (an SPHK2 inhibitor) to venetoclax reduced CLL cell counts (CD19+, CD5+) by 50% compared to controls in mice.
- Mechanism of Action: The study suggests opaganib may reduce T-cell-induced activation and proliferation of venetoclax-resistant cells, potentially resensitizing resistant CLL cells to treatment.
- Current Clinical Status: Opaganib is currently undergoing a Phase 2 clinical trial in combination with darolutamide for advanced prostate cancer. A Phase 1 chemoradiotherapy study protocol is ready for FDA-IND submission.
- Safety Profile: Opaganib has demonstrated a safety and tolerability profile in more than 470 clinical trial and expanded access participants.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Management views the data as a breakthrough potential for maintaining venetoclax effectiveness and reducing resistance-related treatment failure in CLL. The company highlights opaganib's broad potential across oncology, virology, inflammation, diabetes, and obesity, supported by U.S. government partnerships (BARDA, NIAID) for medical countermeasures.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers. Key risks identified include:
- Opaganib may not replicate its potential to mitigate resistance in human CLL therapy.
- Uncertainty regarding the strategic transaction with Cumberland Pharmaceuticals for Talicia.
- Risk of failing to maintain compliance with Nasdaq listing requirements, specifically minimum stockholders' equity.
- Dependence on U.S. government funding, which can be ceased at any time.
- Regulatory risks, including the FDA not agreeing with proposed development plans or requiring additional studies.
Investor Verification Checklist
- Verify the company's current cash position and runway, as no financial data is provided in this filing.
- Confirm the status of Nasdaq compliance regarding minimum stockholders' equity requirements.
- Review the terms and financial impact of the co-commercialization agreement with Cumberland Pharmaceuticals for Talicia.
- Monitor the timeline and design of the upcoming Phase 2 study for opaganib in CLL, if initiated.
- Assess the stability of U.S. government funding (BARDA/NIAID) for opaganib's medical countermeasure indications.